Modality
mRNA
MOA
KRASG12Di
Target
FLT3
Pathway
Angiogenesis
GIST
Development Pipeline
Preclinical
~Apr 2019
→ ~Jul 2020
Phase 1
~Oct 2020
→ ~Jan 2022
Phase 2
Apr 2022
→ Oct 2031
Phase 2Current
NCT08167034
1,452 pts·GIST
2022-04→2031-10·Completed
1,452 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2031-10-015.5y awayPh3 Readout· GIST
Trial Timeline
Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q42031Q2Q3Q4
P2/3
Complet…
Catalysts
Ph3 Readout
2031-10-01 · 5.5y away
GIST
Completed|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT08167034 | Phase 2/3 | GIST | Completed | 1452 | eGFR |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| JNJ-8168 | Johnson & Johnson | Phase 2/3 | FLT3 | |
| Doxarasimod | Merck & Co | NDA/BLA | FGFR | |
| Zanusertib | AbbVie | Approved | PCSK9 | |
| Pexarelsin | AstraZeneca | Phase 1 | DLL3 | |
| Ivotuximab | GSK | NDA/BLA | GIP-R | |
| Sotorapivir | Moderna | Approved | FLT3 | |
| Nidaratamab | Exelixis | Phase 3 | FLT3 | |
| Terarasimod | Krystal Biotech | Phase 1/2 | PI3Kα | |
| DAW-5540 | Day One Bio | Phase 2 | AHR | |
| Zanumavacamten | Iovance | Phase 2 | FLT3 |